Jay A. Berzofsky, M.D., Ph.D.
Vaccine Branch
Branch Chief
National Cancer Institute
10 Center Drive MSC 1578
Building 10, Room 6B04
Bethesda, MD 20892
Fax: 301-480-0681
berzofsk@helix.nih.gov
Dr. Berzofsky was appointed chief of the new Vaccine Branch, Center for Cancer Research, National Cancer Institute, in 2003 after having served as chief of the Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, NIH, since 1987. He graduated Summa cum Laude from Harvard (1967), and received a Ph.D. and M.D. from Albert Einstein College of Medicine. After interning at Massachusetts General Hospital, he joined NIH in 1974. Dr. Berzofsky's research has focused on antigen processing and presentation by MHC molecules, the structure of antigenic determinants, cytokine and regulatory cell control of T cell function and avidity, and translation to the design of vaccines for AIDS, malaria, cancer, and viruses causing cancer. He has published more than 460 scientific works. Dr. Berzofsky has received a number of awards, including the U.S. Public Health Service Superior Service Award, the 31st Michael Heidelberger Award, the McLaughlin Visiting Professorship, the Australasian Society for Immunology Visiting Lectureship, and the Tadeusz J. Wiktor Memorial Lectureship. He is the past president of the American Society for Clinical Investigation, and a fellow of the American Association for the Advancement of Science and was elected Distinguished Alumnus of the Year for 2007 by the Albert Einstein College of Medicine. He was also elected chair of the Medical Sciences Section of the American Association for the Advancement of Science (AAAS) 2007-08. He won the NIH Director's Award and NCI Merit Award in 2008 and a Merit Award in 2011.
Dr. Berzofsky's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
Back to Top
